廣告
香港股市 已收市

  • 恒指

    18,335.32
    -95.07 (-0.52%)
     

  • 國指

    6,556.10
    -31.67 (-0.48%)
     

  • 上證綜指

    3,005.44
    -12.61 (-0.42%)
     

  • 道指

    38,834.86
    +56.76 (+0.15%)
     

  • 標普 500

    5,487.03
    +13.80 (+0.25%)
     

  • 納指

    17,862.23
    +5.21 (+0.03%)
     

  • Vix指數

    12.59
    +0.11 (+0.88%)
     

  • 富時100

    8,230.77
    +25.66 (+0.31%)
     

  • 紐約期油

    81.71
    +0.14 (+0.17%)
     

  • 金價

    2,353.30
    +6.40 (+0.27%)
     

  • 美元

    7.8039
    -0.0023 (-0.03%)
     

  • 人民幣

    0.9298
    +0.0007 (+0.08%)
     

  • 日圓

    0.0490
    -0.0001 (-0.31%)
     

  • 歐元

    8.3657
    -0.0216 (-0.26%)
     

  • Bitcoin

    66,101.59
    +863.92 (+1.32%)
     

  • CMC Crypto 200

    1,374.86
    -7.80 (-0.56%)
     

Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?

Zacks Equity Research
·2 分鐘文章

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Is This 1 Momentum Stock a Screaming Buy Right Now?

Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

廣告

Corcept Therapeutics (CORT)

Menlo Park, CA-based Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone.

CORT boasts a Momentum Style Score of B and VGM Score of B, and holds a Zacks Rank #3 (Hold) rating. Shares of Corcept Therapeutics has seen some interesting price action recently; the stock is down 8.6% over the past one week and up 14.4% over the past four weeks. And in the last one-year period, CORT has gained 35.9%. As for the stock's trading volume, 1,052,113.88 shares on average were traded over the last 20 days.

A company's earnings performance is important for momentum investors as well. For fiscal 2024, two analysts revised their earnings estimate higher in the last 60 days for CORT, while the Zacks Consensus Estimate has increased $0.03 to $0.95 per share. CORT also boasts an average earnings surprise of 31.3%.

CORT should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research